
Progression-Free Probability
100
90
80
70
60
50
40
30
20
10
0
0
10
20
30
40
50
60
70
Months after Surgery
TGF-b 1 ≤ 4.9 ng/mL (median)
TGF-b 1 > 4.9 ng/mL (median)
TGF-b 1
3 yr.
5 yr.
≤ 4.9 ng/mL
95.1 ± 5.4 %
93.4 ± 6.3 %
> 4.9 ng/mL
85.8 ± 9.1 %
74.8 ± 12.1 %
Log rank test
P = .0105

Fig 1

20/020 T98T/00T



Fig 2


Progression-Free Probability
100
90
80
70
60
50
40
30
20
10
0
0
10
20
30
40
50
60
70
Months after Surgery
IGFBP-2 > 437.4 ng/mL (median)
IGFBP-2 ≤ 437.4 ng/mL (median)
IGFBP-2 | 3 yr. ± SE | 5 yr. ± SE
≤ 437.4 ng/mL | 88.2 ± 4.2 % | 76.9 ± 5.7 %
> 437.4 ng/mL | 93.2 ± 3.3 % | 93.2 ± 3.3 %
Log rank test
P = .0310

Fig 4


Progression-Free Probability
100
90
80
70
60
50
40
30
20
10
0
0
10
20
30
40
50
60
70
Months after Surgery
IGFBP-3 > 3239 ng/mL (median)
IGFBP-3 ≤ 3239 ng/mL (median)
IGFBP-3 | 3 yr. ± SE | 5 yr. ± SE
≤ 3239 ng/mL | 84.7 ± 4.7 % | 78.7 ± 5.5 %
> 3239 ng/mL | 96.7 ± 2.3 % | 90.5 ± 4.1 %
Log rank test
P = .0587

Fig 3

20120207 T3817007







Fig 5

20/020 T98T/00T



Fig 6 A

20/020 T987/00T



Fig 6B


PSA Progression -Free Probability
100
90
80
70
60
50
40
30
20
10
0
0
10
20
30
40
50
60
70
Months after Radical Prostatectomy
Soluble Receptor IL-6≤ 25.4 ng/mL (median)
Soluble Receptor IL-6 > 25.4 ng/mL (median)
Log rank test
P = .0026

Fig 7


IL-6 (ng/mL)
40
30
20
10
0
N =
44
66
6
21
6
5
3
2
19
10
Healthy controls
T2 non recur
T2 recur
T3a non recur
T3a recur
T3b non recur
T3b recur
Lymph node metastase
Lymph node metastase
Bone metastases

Fig 8


Soluble Receptor IL-6 (ng/mL)
150
100
50
0
N =
44
66
6
21
6
5
3
2
19
10
Healthy controls
T2 non recur
T2 recur
T3a non recur
T3a recur
T3b non recur
T3b recur
Lymph node metastase
Lymph node metastase
Bone metastases

Fig 9

03/26/2003 15:32 2403



Figure10

20120207 135 2007



Figure 11

Preoperative Prediction of PSA-Progression Free Survival in the 468 Prostatectomy Patients

Multivariate Cox Proportional Hazards Analysis

Factor	p-value	Hazards Ratio	95% CI
Preop PSA	0.005	1.761	1.181-2.625
Bx Gleason Sum	<0.001	2.896	1.630-5.145
Clinical Stage	0.879	1.039	0.633-1.707
Preop TGF-β_1	<0.001	1.170	1.078-1.270
Preop IL-6	0.077	1.038	0.996-1.082
Preop IL-6 sR	0.038	1.215	1.011-1.461

Fig 12

Comparison of Predictive Value of Pre-op versus Post-op Levels for PSA-Progression Free Survival in 468 Prostatectomy Patients

Multivariate Cox Proportional Hazards Analyses
(All models included preop PSA, ECE, Gleason, SVI, SM)

Factor	p-value	Hazards Ratio	95% CI
Preop TGF-β_1	0.400	1.074	0.909-1.269
Postop TGF-β_1	0.001	1.285	1.112-1.486
Preop IL-6	0.042	1.249	1.008-1.546
Postop IL-6	0.297	1.132	0.897-1.429
Preop IL-6 sR	0.020	1.174	1.011-1.241
Postop IL-6 sR	0.224	0.966	0.915-1.021

Fig X13